Clinical Insights: July 19, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration…
Clinical Insights: October 2, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Verzenio™ (abemaciclib) – September 28, 2017 – The U.S. Food and Drug Administration approved Verzenio™ (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth…
Clinical Insights: August 18, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Besponsa® (inotuzumab ozogamicin) – August 17, 2017 – The U.S. Food and Drug Administration approved Besponsa® (inotuzumab ozogamicin) for the treatment of adults with relapsed or…
Clinical Insights: August 11, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval CaroSpir® (spironolactone) – August 7, 2017 – CMP Pharma announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company’s New…
Clinical Insights: August 4, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Vyxeos™ (cytarabine and daunorubicin) – August 3, 2017 – The U.S. Food and Drug Administration approved Vyxeos™ for the treatment of adults with two types of acute…
Clinical Insights: July 7, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Endari™ (L-glutamine oral powder) – July 7, 2017 – The U.S. Food and Drug Administration approved Endari (L-glutamine oral powder) for patients age five years and older…